Pfizer Explores mRNA Technology Beyond COVID-19
Following the success of its COVID-19 vaccine, Pfizer is investigating mRNA technology for potential applications in infectious diseases like influenza and shingles, as well as rare genetic disorders.
Pfizer Inc. is leveraging its experience with messenger RNA (mRNA) technology, proven through its COVID-19 vaccine, to explore new therapeutic and vaccine candidates. The pharmaceutical company announced it is expanding research into mRNA's potential for treating other infectious diseases and rare genetic conditions.
The company has initiated Phase 3 studies for an mRNA-based influenza vaccine candidate. This approach offers flexibility, allowing for rapid updates to target circulating flu strains more effectively than traditional annual vaccines. Pfizer anticipates this could lead to improved efficacy and a more reliable supply.
In collaboration with BioNTech, Pfizer is also developing an mRNA vaccine for shingles, with human studies planned to begin in 2023. Furthermore, Pfizer is partnering with Beam Therapeutics to investigate mRNA as a platform for gene editing therapies aimed at rare genetic liver, muscle, and central nervous system diseases, potentially offering one-time treatments.
Alongside these advancements, Pfizer continues its work on COVID-19 vaccines, including bivalent vaccines for emerging variants and research into a combined COVID-19 and influenza vaccine.